Abstract
The binding mode analysis of Gefitinib revealed that 6-propylmorpholino group (sidechain) shows no interactions due to its weak electron density. In order to modify the electron density of Gefitinib’s sidechain, novel pyrrolidino analogs of Gefitinib where morpholino groups were replaced by substituted pyrrolidino groups were synthesized. Gefitinib derivatives with high electronegativity atoms or groups in the pyrrolidino moiety always exhibit high potent activity against EGFR and human cancer cell lines, A431, MDA-MB-231 and A549. Among these derivatives, 16 displayed the best pharmacokinetic properties that make it to be a promising candidate for developing drugs to replace Gefitinib.
Keywords: Gefitinib, anticancer, EGFR, pyrrolidino analogue, pharmacokinetic property.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Pyrrolidino Analogues of Gefitinib with Improved EGFR Inhibition, Cancer Cell Cytotoxicity, and Pharmacokinetic Properties
Volume: 16 Issue: 12
Author(s): Jing-Kun Fang, Zhimin Xu, Yingjun Zhang, Weihong Zhang, Bing Liu, Yu Fang and Tengxiao Sun
Affiliation:
Keywords: Gefitinib, anticancer, EGFR, pyrrolidino analogue, pharmacokinetic property.
Abstract: The binding mode analysis of Gefitinib revealed that 6-propylmorpholino group (sidechain) shows no interactions due to its weak electron density. In order to modify the electron density of Gefitinib’s sidechain, novel pyrrolidino analogs of Gefitinib where morpholino groups were replaced by substituted pyrrolidino groups were synthesized. Gefitinib derivatives with high electronegativity atoms or groups in the pyrrolidino moiety always exhibit high potent activity against EGFR and human cancer cell lines, A431, MDA-MB-231 and A549. Among these derivatives, 16 displayed the best pharmacokinetic properties that make it to be a promising candidate for developing drugs to replace Gefitinib.
Export Options
About this article
Cite this article as:
Fang Jing-Kun, Xu Zhimin, Zhang Yingjun, Zhang Weihong, Liu Bing, Fang Yu and Sun Tengxiao, Pyrrolidino Analogues of Gefitinib with Improved EGFR Inhibition, Cancer Cell Cytotoxicity, and Pharmacokinetic Properties, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (12) . https://dx.doi.org/10.2174/1871520616666160622094153
DOI https://dx.doi.org/10.2174/1871520616666160622094153 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets Adhesion Molecules as Targets for the Treatment of Neoplastic Diseases
Current Pharmaceutical Design Depleted Uranium and Human Health
Current Medicinal Chemistry Deep Inspiration Breath-hold (DIBH) Technique to Reduce Cardiac Radiation Dose in the Management of Breast Cancer
Current Cancer Therapy Reviews Epigenetic Therapies and Potential Drugs for Treating Human Cancer
Current Drug Targets Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94
Current Topics in Medicinal Chemistry Synthesis and Anticancer Activity of 9-O-Pyrazole Alkyl Substituted Berberine Derivatives
Anti-Cancer Agents in Medicinal Chemistry EMT Blockage Strategies: Targeting Akt Dependent Mechanisms for Breast Cancer Metastatic Behaviour Modulation
Current Gene Therapy A Systematic Review of Genes Involved in the Inverse Resistance Relationship Between Cisplatin and Paclitaxel Chemotherapy: Role of BRCA1
Current Cancer Drug Targets Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands
Current Medicinal Chemistry Hsp90: A Novel Target for Cancer Therapy
Current Topics in Medicinal Chemistry Tyrosine Kinase Inhibitors, Pancreatic Hyperenzymemia and Acute Pancreatitis: A Review
Recent Patents on Inflammation & Allergy Drug Discovery Genistein as a Potential Anticancer Agent Against Head and Neck Squamous Cell Carcinoma
Current Topics in Medicinal Chemistry Cell Cycle Checkpoint Genes and Aneuploidy: A Short Review
Current Genomics Targeting Apoptotic Signaling Pathways in Human Lung Cancer
Current Cancer Drug Targets Evaluation of Angiogenesis with the Expression of VEGF-C and CD34 in Human Colon Cancer
Current Chemical Biology Advances in the Development of Bradykinin Receptor Ligands
Current Topics in Medicinal Chemistry Oncolytic Virotherapy for Breast Cancer Treatment
Current Gene Therapy An Overview of Synthesis of Indole Alkaloids and Biological Activities of Secondary Metabolites Isolated from Hyrtios Species
Mini-Reviews in Medicinal Chemistry Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy